| Symbol | NVCT |
|---|---|
| Name | NUVECTIS PHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1 BRIDGE PLAZA,SUITE 275, FORT LEE, New Jersey, 07024, United States |
| Telephone | +1 201 614-3150 |
| Fax | — |
| — | |
| Website | https://www.nuvectis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001875558 |
| Description | Nuvectis Pharma Inc is a biopharmaceutical company. Additional info from NASDAQ: |
Mosseri Marlio Charles 🟢 acquired 50.0K shares of Nuvectis Pharma, Inc. (NVCT) at $18.32 Transaction Date: Jun 30, 2026 | Filing ID: 079793
Read moreDirector BENTSUR RON 🟢 acquired 12.5K shares of Nuvectis Pharma, Inc. (NVCT) at $20.00 Transaction Date: Jun 30, 2026 | Filing ID: 079792
Read moreNuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
Read moreNuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
Read moreNew Form 424B5 - Nuvectis Pharma, Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001104659-26-078864 <b>Size:</b> 527 KB
Read more(90% Positive) NUVECTIS PHARMA, INC. (NVCT) Provides Update on trial for Lupus Nephritis (LN)
Read moreNuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Read moreNuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07315113 | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Sm… | Phase1 | EGFR Mutation Positive Non-small Cell Lung Cancer | Recruiting | 2025-12-18 | 2027-06-01 | ClinicalTrials.gov |
| NCT05873686 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Phase1 | Advanced Solid Tumor | Recruiting | 2023-10-26 | 2027-07-01 | ClinicalTrials.gov |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expans… | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2021-12-31 | 2025-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| NXP800 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05226507 |
| Osimertinib | Other | Phase PHASE1 | EGFR Mutation Positive Non-small Cell Lung Cancer | RECRUITING | NCT07315113 |
| NXP900 | Other | Phase PHASE1 | EGFR Mutation Positive Non-small Cell Lung Cancer | RECRUITING | NCT07315113 |
| NXP900 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05873686 |
| Osimertinib | DRUG | Phase PHASE1 | EGFR Mutation Positive Non-small Cell Lung Cancer | RECRUITING | NCT07315113 |
| NXP900 | DRUG | Phase PHASE1 | EGFR Mutation Positive Non-small Cell Lung Cancer | RECRUITING | NCT07315113 |
| NXP800 | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05226507 |